Neutropenic Patients
▸ Click on the following categories to expand treatment regimens.
|
Gram-Negative Bacteria
|
Preferred Regimen
|
▸ [[
|
Alternative Regimen
|
▸ '''''
|
|
Gram-Positive Bacteria
|
Preferred Regimen
|
Alternative Regimen
|
▸ [[
|
▸ [
|
|
Nocardia spp
|
Preferred Regimen
|
▸ TMP-SMX x 3-12 months
|
Alternative Regimen 1
|
▸ Sulfadiazine 2-4 g PO 1 dose
|
FOLLOWED BY
|
▸ Sulfadiazine 2-4 g/day PO q4-8h x 3-12 months
|
Alternative Regimen 1
|
▸ Imipenem 250-500 mg IV q6-8h x 3-12 months
|
|
Atypical mycobacteria
|
Preferred Regimen
|
▸ [[
|
Alternative Regimen
|
▸ [[
|
|
Varicella-zoster virus
|
Preferred Regimen
|
▸ Acyclovir 10 mg/kg IV (infusion over 1 hour) q8h x 7-10 days OR ▸ Famciclovir x 7-10 days OR ▸ Valacyclovir x 7-10 days
|
Alternative Regimen
|
▸ [[
|
|
Herpes simplex virus
|
Preferred Regimen
|
▸ Acyclovir 10 mg/kg IV (infusion over 1 hour) q8h x 7-10 days
|
Alternative Regimen
|
▸ Famciclovir PO x 7 days OR ▸ Valacyclovir PO x 7 days
|
|
Cytomegalovirus
|
Preferred Regimen
|
▸ Ganciclovir x 21 days
|
Alternative Regimen
|
▸ [[
|
|
|
Cellular Immune Deficient Patients
- ↑ Wheat, LJ.; Freifeld, AG.; Kleiman, MB.; Baddley, JW.; McKinsey, DS.; Loyd, JE.; Kauffman, CA. (2007). "Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America". Clin Infect Dis. 45 (7): 807–25. doi:10.1086/521259. PMID 17806045.